Akash Mukherjee is an Oncology physician affiliated with Oncology Hematology Care. OpenAlex indexes 69 publications with 283 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4777 E Galbraith Rd Ste 320
Cincinnati, OH 452362725
Telephone
513-751-2273Provider last certified this registry record 9 Apr 2026.
Industry payments
30 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year202510 payments$25,163openpaymentsdata.cms.gov ↗
- BeOne Medicines USA, Inc.Program year20259 payments$10,891openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.8%CD38-directed Cytolytic Antibody48%Daratumumab100%Part B, office-administered≥12 patientsBCL-2 Inhibitor0.4%Venclexta100%Part D≥15 patients+ 6 more classes in this area
Anti-infectives
26.9%Human Immunoglobulin G24.5%Immune globulin100%Part B, office-administered≥26 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor0.9%Valacyclovir100%Part D≥34 patients+ 4 more classes in this area
Sensory organs
13%Corticosteroid13%Dexamethasone sodium phosphate98%Dexamethasone2%Part D + Part B≥30 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pathways for India to Reduce Ambient Air Pollution Health Burden and Achieve the Sustainable Development Goal (SDG-3.4)
Environmental Science & Technology
2025 - Safety and efficacy of outpatient CAR-T therapy in a community-based medical center.
Journal of Clinical Oncology
2025 - Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease
Cell Host & Microbe
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Jamie Waselenko, MD
Oncology Hematology Care
Edward Faber, DO, MS
Oncology Hematology Care
Bernard Hertzman, MD
Oncology Hematology Care
David Drosick, MD
Oncology Hematology Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”